Pharma BD Deal Intelligence
Illumina and Amgen entered a multi-year collaboration to leverage Illumina's population-scale genomics capabilities and Amgen's proprietary deCODE genetics database to advance drug discovery and development. The collaboration utilizes whole genome sequencing data from deCODE's database of more than 500,000 consented participants. Financial terms were not publicly disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Illumina, Inc. / Amgen Inc. (this deal) | 2020 | — | 56 |
| Illumina, Inc. / GRAIL, Inc. | 2020 | $8.0B | 36 |
| Illumina, Inc. / GRAIL, Inc. | 2021 | $7.1B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
← Browse all deals · How we score deals
More: 2020 deals · Illumina, Inc. deals